Matching articles for "Cortiment"

Drugs for Inflammatory Bowel Disease

   
The Medical Letter on Drugs and Therapeutics • July 10, 2023;  (Issue 1680)
Ulcerative colitis (UC) and Crohn's disease (CD), referred to collectively as inflammatory bowel disease (IBD), are chronic immune-mediated inflammatory conditions. Guidelines for treatment of UC and...
Ulcerative colitis (UC) and Crohn's disease (CD), referred to collectively as inflammatory bowel disease (IBD), are chronic immune-mediated inflammatory conditions. Guidelines for treatment of UC and CD have been updated in recent years
Med Lett Drugs Ther. 2023 Jul 10;65(1680):105-12 | Show Full IntroductionHide Full Introduction

Ozanimod (Zeposia) for Ulcerative Colitis

   
The Medical Letter on Drugs and Therapeutics • September 20, 2021;  (Issue 1633)
The oral sphingosine 1-phosphate (S1P) receptor modulator ozanimod (Zeposia – Bristol Myers Squibb) has been approved by the FDA for treatment of adults with moderately to severely active ulcerative...
The oral sphingosine 1-phosphate (S1P) receptor modulator ozanimod (Zeposia – Bristol Myers Squibb) has been approved by the FDA for treatment of adults with moderately to severely active ulcerative colitis. It is the first S1P receptor modulator to be approved for treatment of ulcerative colitis. Ozanimod was approved in March 2020 for use in adults with relapsing forms of multiple sclerosis.
Med Lett Drugs Ther. 2021 Sep 20;63(1633):147-51 | Show Full IntroductionHide Full Introduction

In Brief: Extended-Release Budesonide (Ortikos) for Crohn's Disease

   
The Medical Letter on Drugs and Therapeutics • November 2, 2020;  (Issue 1610)
An oral extended-release formulation of the corticosteroid budesonide (Ortikos – Ferring) is now available for once-daily treatment of mild to moderate active Crohn's disease of the ileum and/or ascending...
An oral extended-release formulation of the corticosteroid budesonide (Ortikos – Ferring) is now available for once-daily treatment of mild to moderate active Crohn's disease of the ileum and/or ascending colon in patients ≥8 years old and for maintenance of remission for up to 3 months in adults. Ortikos is the second oral formulation of budesonide to be approved for this indication; Entocort EC, an ileal-release formulation, was the first. A third oral formulation of budesonide (Uceris) is approved for induction of remission in patients with mild to moderate active ulcerative colitis.
Med Lett Drugs Ther. 2020 Nov 2;62(1610):176 | Show Full IntroductionHide Full Introduction

Drugs for Inflammatory Bowel Disease

   
The Medical Letter on Drugs and Therapeutics • July 2, 2018;  (Issue 1550)
Management of both ulcerative colitis (UC) and Crohn's disease (CD) is based on disease severity. Disease location (proctitis, left-sided colitis, or extensive colitis) also plays a role in drug selection....
Management of both ulcerative colitis (UC) and Crohn's disease (CD) is based on disease severity. Disease location (proctitis, left-sided colitis, or extensive colitis) also plays a role in drug selection. Some drugs for induction and maintenance of remission of inflammatory bowel disease (IBD) are listed in Table 1.
Med Lett Drugs Ther. 2018 Jul 2;60(1550):107-14 | Show Full IntroductionHide Full Introduction